10-Q
Quarterly Report
ADIAL PHARMACEUTICALS, INC.
ADIL
NASDAQ
CIK: 1513525
File #: 001-38323
Balance Sheet
27 line items · 2 periods
XBRL
| Item | Sep 30, 2024 | Dec 31, 2023 |
|---|---|---|
ASSETS | ||
Current Assets: | ||
Cash and cash equivalents | 5,204,346 | 2,827,082 |
Prepaid research and development | 4,430 | — |
Prepaid expenses and other current assets | 409,807 | 371,597 |
Total Current Assets | 5,618,583 | 3,198,679 |
Intangible assets, net | 3,489 | 3,913 |
Equity method investment | 1,090,647 | 1,534,013 |
Equity Method Investments | 1,090,647 | 1,534,013 |
Total Assets | 6,712,719 | 4,736,605 |
LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
Current Liabilities: | ||
Accounts payable | 318,118 | 103,325 |
Related Party | — | 24,062 |
Accrued expenses | 500,928 | 477,747 |
Related Party | 10,000 | 47,942 |
Total Current Liabilities | 829,046 | 653,076 |
Total Liabilities | 829,046 | 653,076 |
Stockholders’ Equity | ||
Common Stock, 50,000,000 shares authorized with a par value of $0.001 per share, 6,405,781 and 1,663,421 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively | 6,404 | 1,663 |
Additional paid in capital | 85,801,802 | 72,879,738 |
Accumulated deficit | (79,924,533) | (68,797,872) |
Total Stockholders’ Equity | 5,883,673 | 4,083,529 |
Common Stock | 6,404 | 1,663 |
Additional Paid In Capital | 85,801,802 | 72,879,738 |
Accumulated Deficit | (79,924,533) | (68,797,872) |
Total Liabilities and Stockholders’ Equity | 6,712,719 | 4,736,605 |